Table 3.

Predictors of SBP trajectory group membership and level across the menopause transition, (n=3302) ^*

Variables‡	SBP trajectory group, n (%)
	Low-accelerated rise 1172 (35%)	Medium-linear rise 1574 (48%)	High-slow decline 556 (17%)
Predictors of SBP trajectory group membership, OR (95% CI) §
Race/ethnicity
White	1 [ref]	[ref]	1 [ref]
Black	0.30 (0.22, 0.42)	[ref]	3.08 (2.28, 4.17)
Hispanic	0.29 (0.08, 1.13)	[ref]	3.33 (1.11, 10.01)
Japanese	0.44 (0.27, 0.70)	[ref]	1.63 (0.69, 3.86)
Chinese	0.37 (0.23, 0.61)	[ref]	2.84 (1.03, 7.84)
Baseline BMI (per 1-SD increase)	0.33 (0.28, 0.39)	[ref]	1.50 (1.33, 1.70)
Age at menopause
Before 51 years	1.73 (1.31, 2.28)	[ref]	1.06 (0.78, 1.45)
Between 51 and 53 years	1 [ref]	[ref]	1 [ref]
After 53 years	0.75 (0.58, 0.98)	[ref]	1.34 (1.00, 1.80)
Baseline estradiol† (per 1-SD increase)	1.01 (0.89, 1.14)	[ref]	1.11 (0.96, 1.28)
Baseline FSH† (per 1-SD increase)	1.00 (0.87, 1.14)	[ref]	1.10 (0.95, 1.26)
Baseline vasomotor symptoms	0.80 (0.64, 1.00)	[ref]	1.21 (0.95, 1.54)
Predictors of SBP level over time within each trajectory group, beta (SE) §
Estradiol† (per 1-SD increase)	0.11 (0.12)	−0.12 (0.13)	0.14 (0.23)
FSH† (per 1-SD increase)	−0.16 (0.10)	−0.39 (0.12)	−0.06 (0.22)
Vasomotor symptoms	0.92 (0.30)	1.17 (0.30)	0.96 (0.52)
Hormone therapy use	0.65 (0.43)	0.57 (0.42)	−1.57 (0.84)
LDL-C (per 1-SD increase)	0.39 (0.16)	0.30 (0.16)	0.42 (0.24)
Diabetes	4.93 (0.93)	5.36 (0.56)	4.92 (0.80)

^*Bold indicates P-value <0.05. Actual p-values are provided in table S12

^†Log-transformed

^‡Model further adjusted for site and cycle-day of blood draw. There were 107 (3%) women excluded from this model due to missing covariate values (BMI [42], baseline estradiol [8], baseline FSH [1], baseline vasomotor symptoms [18], LDL-C [38])

^§Estimates of SBP trajectory group membership and level are from the same model

LDL-C: low-density lipoprotein cholesterol, SBP: systolic blood pressure